Santhera Shareholders Approve all Board Proposals at Annual Shareholders' Meeting
(Thomson Reuters ONE) -
Santhera Pharmaceuticals Holding AG /
Santhera Shareholders Approve all Board Proposals at Annual Shareholders'
Meeting
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Liestal, Switzerland, April 23, 2012 - Santhera Pharmaceuticals (SIX: SANN)
announced that all proposals at today's annual shareholders' meeting passed with
a vast majority. Santhera's shareholders approved the annual report, the annual
financial statements and the consolidated financial statements for 2011.
Santhera's shareholders voted in favor of the proposed appropriation of the
results, the renewal of authorized and the increase of conditional share
capital. The annual shareholders' meeting also granted discharge to the members
of the Board of Directors and management. Klaus Schollmeier and Timothy Rink
were re-elected as Board members for a period of one and three years,
respectively. The shareholders also re-elected Ernst & Young as auditors. A
total of 1,691,639 shares or 46.05 % of the share capital was represented at the
Annual Shareholders' Meeting.
In his presentation to shareholders, Thomas Meier, Chief Executive Officer,
reported on significant progress with the Company's key projects and the impact
of last year's restructuring: "In Europe, we submitted the application for
marketing authorization of idebenone (Catena(®)) in Leber's Hereditary Optic
Neuropathy (LHON). The revenues from product sales combined with strict cost
control measures safeguarded Santhera's cash reserves." Looking into 2012 he
continued: "We expect a decision from the European Medicines Agency on the LHON
filing in the second half of the year. If approved, this would be our second
product approval. With a significantly reduced cash burn the financing of
Santhera's current business focus on key value drivers is secured into 2013."
* * *
About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company
focused on the development and commercialization of innovative pharmaceutical
products for the treatment of orphan neuromuscular and mitochondrial diseases,
areas of high unmet medical with no current therapies. Santhera's first product
Catena(®) is currently marketed in Canada to treat Friedreich's Ataxia.
Catena(®) is also under review for marketing authorization by the European
Medicine Agency as the first therapy for patients suffering from Leber's
Hereditary Optic Neuropathy. For further information, please visit
www.santhera.com.
Catena(®) is a trademark of Santhera Pharmaceuticals.
For further information, contact
Thomas Meier, Chief Executive Officer
Phone: +41 61 906 89 64
thomas.meier(at)santhera.com
Thomas Staffelbach, Vice President, Head Public & Investor Relations
Phone: +41 61 906 89 47
thomas.staffelbach(at)santhera.com
Disclaimer/Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for
or purchase any securities of Santhera Pharmaceuticals Holding AG. This
publication may contain certain forward-looking statements concerning the
Company and its business. Such statements involve certain risks, uncertainties
and other factors which could cause the actual results, financial condition,
performance or achievements of the Company to be materially different from those
expressed or implied by such statements. Readers should therefore not place
undue reliance on these statements, particularly not in connection with any
contract or investment decision. The Company disclaims any obligation to update
these forward-looking statements.
News release ASM 2012:
http://hugin.info/137261/R/1604971/508013.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Santhera Pharmaceuticals Holding AG via Thomson Reuters ONE
[HUG#1604971]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 23.04.2012 - 08:33 Uhr
Sprache: Deutsch
News-ID 1105921
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Liestal
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 62 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Santhera Shareholders Approve all Board Proposals at Annual Shareholders' Meeting
"
steht unter der journalistisch-redaktionellen Verantwortung von
Santhera Pharmaceuticals Holding AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
